August 17, 2022 Bochum, Germany.

Adding to their already extensive global reach, Wallaby / phenox today announced the introduction of the pRESET® mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke into Brazil. This latest expansion into the Brazilian market marks a first product launch since the acquisition of phenox by Wallaby Medical in April 2022. With the introduction of pRESET® to Brazil, Wallaby / phenox will continue to demonstrate their combined ability to bring devices to new regions whilst maintaining their reputation for the highest quality devices on the market.

“This is a very exciting time for Wallaby Medical, supporting our physicians in Brazil is the next logical step. With Brazil having the world’s 7th largest population we are reaching even more lives affected by stroke. We look forward to helping patients in LATAM with our best-in-class pRESET® thrombectomy device.”- Michael Alper, CEO, Wallaby Medical

Wallaby / phenox will continue to bring their innovative, highest quality devices to new markets with the aid of the acquisition of phenox by Wallaby. Access to new markets will inevitably be improved with the merging of the two companies. The end goal being to reach the most lives affected by stroke worldwide. Patient outcomes are at the forefront of innovation at Wallaby / phenox and devices are engineered with the objective of improving lives throughout the world.

“As commercial leader, I am delighted to announce the launch of pRESET® in Brazil. Saving patient’s lives is at the absolute core of phenox and the purpose of its employees. The future is bright for phenox and Wallaby.” - Peter Cooke, Commercial Leader, phenox GmbH.